Dose Proportionality of TFV-DP in Mucosal Tissue, and Endogenous Nucleotide Quantification, After a Single Dose of GS-7430 in Women

Trial Profile

Dose Proportionality of TFV-DP in Mucosal Tissue, and Endogenous Nucleotide Quantification, After a Single Dose of GS-7430 in Women

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs Tenofovir alafenamide (Primary)
  • Indications Hepatitis B; HIV-1 infections
  • Focus Pharmacokinetics
  • Most Recent Events

    • 24 Mar 2017 Results published in the Journal of Antimicrobial Chemotherapy
    • 29 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 04 Nov 2015 Status changed from recruiting to active, no longer recruiting as per the protocol amendment reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top